Anti-programmed cell death protein 1 (PD-1) inhibitors of nivolumab (7) and pembrolizumab (8), anti-CTLA-4 inhibitors of tremelimumab (9) and ipilimumab (10), the preliminary results showed promising antitumor activity in HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.